EXHIBIT 10.24

 

THIRD AMENDMENT TO THE

AMENDED AND RESTATED LICENSE AGREEMENT

 

THIS THIRD AMENDMENT TO THE AMENDED AND RESTATED LICENSE AGREEMENT (“Amendment”)
made as of the 21st day of March, 2005, by and between VASCULAR GENETICS INC., a
Delaware corporation (the “Licensee”) and HUMAN GENOME SCIENCES, INC., a
Delaware corporation (“HGS”).

 

WHEREAS, HGS and the Licensee entered into that certain License Agreement, dated
as of October 31, 1997 (“Original License Agreement”), whereunder HGS granted to
the Licensee an exclusive license to use the gene Vascular Endothelial Growth
Factor 2 in gene therapy treatment of vascular diseases; and

 

WHEREAS, the parties amended the Original License Agreement in its entirety with
that certain Amended and Restated License Agreement, dated February 28, 2001,
and further amended such document by a First Amendment to Amended and Restated
License Agreement dated October 10, 2002 and a Second Amendment to Amended and
Restated License Agreement dated April 26, 2004 (collectively “Amended License
Agreement”); and

 

WHEREAS, the parties desire to herein amend the Amended License Agreement.

 

NOW, THEREFORE, for and in consideration of the premises and mutual promises
herein contained, and for other good and valuable consideration, the receipt and
sufficiency of which are hereby acknowledged, the parties agree as follows:

 

1. The Parties acknowledge that all capitalized terms not otherwise defined
herein shall have the meaning ascribed to such terms in the Amended License
Agreement.

 

2. Section 1.13. Section 1.13 of the Amended License Agreement (LICENSED FIELD
OF USE) is hereby deleted in its entirety and replaced with the following:

 

LICENSED FIELD OF USE shall mean the field of GENE THERAPY for the treatment of
vascular disease, which for the purpose of this Agreement shall include, but is
not limited to, the treatment of diabetic neuropathy.

 

3. Section 3.2. Section 3.2 of the Amended License Agreement (minimum use
standards) is hereby deleted in its entirety and replaced with the following:

 

LICENSEE agrees that it will meet the following minimum use standards either by
its own performance or through or in combination with an affiliate or
sublicensee.

 

(a) LICENSEE shall have initiated a Phase IIb or Phase III clinical trial no
later than December 31, 2004.

--------------------------------------------------------------------------------

(b) If both a Phase II and Phase III clinical trial are required by FDA,
LICENSEE shall have initiated the Phase III clinical trial no later than six (6)
months after the end of the Phase II meeting, but no later than December 31,
2006.

 

(c) LICENSEE shall have filed a BLA for at least one LICENSED PRODUCT no later
than December 31, 2009.

 

LICENSEE will give notice of meeting each milestone within ten (10) business
days of its occurrence. LICENSEE will provide semi-annual updates to HGS on the
clinical trial progress. For purposes of the above milestone, initiate shall
mean when the first patient is dosed with CLINICAL TRIAL MATERIAL. If FDA
imposes unexpected requirements unrelated to actions by LICENSEE, LICENSEE and
HGS will negotiate in good faith extension of these milestones.

 

4. Except as otherwise expressly stated herein, all provisions of the Amended
License Agreement remain in full force and effect.

 

5. This Amendment may be signed in one or more counterparts, which when taken
together shall constitute one and the same Amendment.

 

IN WITNESS WHEREOF, the parties have executed and delivered this Amendment as of
the date first written above.

 

HGS:

 

HUMAN GENOME SCIENCES, INC.

By:   /s/    James H. Davis        

Name:

  James H. Davis, Ph.D.

Title:

  Executive Vice President

 

LICENSEE:

 

VASCULAR GENETICS INC.

By:   /s/    Richard E. Otto        

Name:

  Richard E. Otto

Title:

  Chief Executive Officer